Chu and co-workers have demonstrated that Silent Information Regulator Type 1 (SIRT1), a class III histone deacetylase (HDAC), is over-expressed in various chemoresistant tumors of cancer patients and inhibition of SIRT1 gene expression leads to decrease in MDR1 expression and increase in drug sensitivity [10]. This evidence concerns the gene HDAC9 and cancer.